Form 4: RELMADA COO Ence Buys 136,000 Shares

RELMADA Therapeutics' Chief Administrative and Operating Officer, Chuck Ence, purchased 136,000 shares of common stock at $2.20 per share.

Summary

• Chuck Ence, the Chief Administrative and Operating Officer (CAO and COO) of RELMADA Therapeutics, Inc. (RLMD), acquired 136,000 shares of the company's common stock.
• The transaction took place on November 5, 2025, with shares purchased at a price of $2.20 per share.
• Following this acquisition, Ence's beneficial ownership in RELMADA Therapeutics totals 403,931 shares of common stock.
• The purchase was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 8

Explanation: The Chief Administrative and Operating Officer's significant purchase of company stock indicates strong confidence in the company's future prospects and valuation.

Positives

• A high-ranking insider, the CAO and COO, made a significant open market purchase of 136,000 shares, signaling strong confidence in the company's future prospects.
• The purchase price of $2.20 per share suggests management believes the stock is currently undervalued or has substantial upside potential.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy by the insider.

Industry Context

Insider purchases, particularly by high-ranking officers like a COO, often signal strong internal confidence in the company's strategic direction and future performance, potentially differentiating it from peers facing uncertainty within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• While specific industry benchmarks for insider buying volume are not directly provided in this filing, a purchase of 136,000 shares by a COO at $2.20 per share represents a notable personal investment.
• This level of insider commitment is generally viewed positively within the biotechnology or pharmaceutical sector, signaling strong internal confidence, though direct comparisons to specific peer company insider transactions would require additional data.

Related Party Transactions

• The purchase of 136,000 shares of common stock by Chuck Ence, the Chief Administrative and Operating Officer, from RELMADA Therapeutics constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal, potentially increasing confidence in the company's valuation and future performance.
• Employees could interpret the officer's personal investment as a sign of stability and belief in the company's long-term success.

Key Dates

Recommendation

The significant purchase of common stock by a key executive, the CAO and COO, at $2.20 per share signals strong internal conviction regarding the company's valuation and future growth prospects. This insider buying activity often precedes positive developments and suggests the stock may be undervalued, making it an attractive 'buy' for investors.

Keywords

RELMADA Therapeutics, RLMD, Insider Trading, Stock Purchase, Chuck Ence, Form 4, Officer Purchase, Rule 10b5-1